SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Neuland Laboratories - Quaterly Results

11 May 2023 Evaluate
A decent increase of about 59.09% in the turnover to Rs. 4070.73 millions was observed for the quarter ended March 2023. The turnover stood at Rs. 2558.73 millions during the similar quarter previous year.The Net Profit of the company vaulted to 287.18% to Rs. 845.10  millions from Rs. 218.27 millions in the previous quarter.Operating Profit saw a handsome growth to 1277.81 millions from 393.44 millions in the quarter ended March 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 4070.73 2558.73 59.09 11911.98 9510.77 25.25 11911.98 9510.77 25.25
Other Income 80.64 6.31 1177.97 97.48 20.77 369.33 97.48 20.77 369.33
PBIDT 1277.81 393.44 224.78 2810.56 1442.71 94.81 2810.56 1442.71 94.81
Interest 42.89 27.70 54.84 130.67 134.94 -3.16 130.67 134.94 -3.16
PBDT 1234.92 365.74 237.65 2679.89 1307.77 104.92 2679.89 1307.77 104.92
Depreciation 134.70 124.52 8.18 527.76 490.36 7.63 527.76 490.36 7.63
PBT 1100.22 241.22 356.11 2152.13 817.41 163.29 2152.13 817.41 163.29
TAX 255.12 22.95 1011.63 520.94 182.06 186.14 520.94 182.06 186.14
Deferred Tax 1.76 -47.35 -103.72 17.04 -22.16 -176.90 17.04 -22.16 -176.90
PAT 845.10 218.27 287.18 1631.19 635.35 156.74 1631.19 635.35 156.74
Equity 129.01 129.01 0.00 129.01 129.01 0.00 129.01 129.01 0.00
PBIDTM(%) 31.39 15.38 104.15 23.59 15.17 55.54 23.59 15.17 55.54

Neuland Laboratories Share Price

17177.50 225.25 (1.33%)
12-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.25
Dr. Reddys Lab 1273.90
Cipla 1388.80
Zydus Lifesciences 1104.35
Lupin 2292.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: